References
1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol . 2013;108(3):308-328. doi:10.1038/ajg.2012.444
2. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.Clin Pharmacokinet . 2001;40(6):411-426. doi:10.2165/00003088-200140060-00003
3. Dean L. Esomeprazole Therapy and CYP2C19 Genotype Drug class : Proton Pump Inhibitors. 2019;(Md):1-7.
4. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther . 2006;44(07):297-302. doi:10.5414/CPP44297
5. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.Aliment Pharmacol Ther . 2001;15(10):1563-1569. doi:10.1046/j.1365-2036.2001.01087.x
6. Anderson GD. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin Pharmacokinet . 2005;44(10):989-1008. doi:10.2165/00003088-200544100-00001
7. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia.Lancet . 2021;398(10297):341-354. doi:10.1016/S0140-6736(20)32335-7
8. Duley L. The Global Impact of Pre-eclampsia and Eclampsia.Semin Perinatol . 2009;33(3):130-137. doi:10.1053/j.semperi.2009.02.010
9. Machano MM, Joho AA. Prevalence and risk factors associated with severe pre-eclampsia among postpartum women in Zanzibar: A cross-sectional study. BMC Public Health . 2020;20(1):1-10. doi:10.1186/s12889-020-09384-z
10. Tong S, Kaitu’u-Lino TJ, Hastie R, Brownfoot F, Cluver C, Hannan N. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia.Am J Obstet Gynecol . September 2020. doi:10.1016/j.ajog.2020.09.014
11. De Silva M, Brownfoot F, Hannan NJ, et al. A Systematic Review of Proton Pump Inhibitors for the Prevention and Treatment of Preeclampsia and Gestational Hypertension. Open J Obstet Gynecol . 2019;09(01):21-28. doi:10.4236/ojog.2019.91003
12. Onda K, Tong S, Beard S, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction.Hypertension . 2017;69(3):457-468. doi:10.1161/HYPERTENSIONAHA.116.08408
13. Cluver CA, Hannan NJ, van Papendorp E, et al. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial.Am J Obstet Gynecol . 2018;219(4):388.e1-388.e17. doi:10.1016/j.ajog.2018.07.019
14. Hunfeld NG, Touw DJ, Mathot RA, et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther . 2010;31(1):150-159. doi:10.1111/j.1365-2036.2009.04150.x
15. Helgadóttir H, Lund SH, Gizurarson S, Waldum H, Björnsson ES. Pharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and females. Scand J Gastroenterol . 2021;56(2):128-136. doi:10.1080/00365521.2020.1859610
16. Persson BA, Lagerström PO, Grundevik I. Determination of omeprazole and metabolites in plasma and urine. Scand J Gastroenterol . 1985;20(S108):71-77. doi:10.3109/00365528509095820
17. Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol . 2013;2(6):1-9. doi:10.1038/psp.2013.24
18. Beal SL. Ways to fit a PK model with some data below the quantification limit - reference for BLQ handling. J Pharmacokinet Pharmacodyn . 2001;28(5):481-504. doi:10.1023/A:1012299115260
19. Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JHM, Huitema ADR. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses - reference for mixture models.AAPS J . 2012;14(3):601-611. doi:10.1208/s12248-012-9373-2
20. Strom CM, Goos D, Crossley B, et al. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med . 2012;14(1):95-100. doi:10.1038/gim.0b013e3182329870
21. Jeong H. Altered drug metabolism during pregnancy: Hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol . 2010;6(6):689-699. doi:10.1517/17425251003677755
22. Papageorgiou I, Grepper S, Unadkat JD. Induction of hepatic CYP3A enzymes by pregnancy-related hormones: Studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos . 2013;41(2):281-290. doi:10.1124/dmd.112.049015
23. Andersson T, Andren K, Cederberg C, Lagerstrom P, Lundborg P, Skanberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol . 1990;29(5):557-563. doi:10.1111/j.1365-2125.1990.tb03679.x
24. Nagase M, Shimada H, Nii M, et al. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes. J Clin Pharm Ther . 2020;45(5):1030-1038. doi:10.1111/jcpt.13129
25. Liu D, Yang H, Jiang J, et al. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers.J Clin Pharmacol . 2016:816-826. doi:10.1002/jcph.733
26. Joseph F Standing, Marie Sandstrom, Tommy Andersson, Kerstin Rohss MOK. Population Pharmacokinetic Modelling of Esomeprazole Nonlinearity - PAGE 18 (2009) Abstract 1577 [www.page-meeting.org/?abstract=1577]. Population Approach Group Europe.
27. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil . 2013;19(1):25-35. doi:10.5056/jnm.2013.19.1.25
28. El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol . 2018;14(4):447-460. doi:10.1080/17425255.2018.1461835
29. Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol . 2000;56(9-10):665-670. doi:10.1007/s002280000206